Guo Y, Ha JY, Piao HL, et al. - Experts aspired to explore whether 3% diquafosol (DQS), a P2Y2 receptor agonist, can preserve the meibomian gland morphology in glaucoma patients treated with prostaglandin analogs (PGA) for a 12-month follow-up period. The sample consisted of 46 normal tension glaucoma patients (84 eyes) who were treated with either preservative-containing PGA (PC-PGA; 16 patients, 28 eyes), preservative-free PGA (PF-PGA; 21 patients, 39 eyes), or a combination of PC-PGA and 3% DQS (PC-PGA + DQS; 9 patients, 17 eyes). Over at least 12 months, combining 3% DQS with PC-PGA was as successful as PF-PGA in maintaining the meibomian gland morphology. The findings indicate that 3% DQS can be a promising strategy for managing patients with glaucoma with a high risk of developing meibomian gland dysfunction due to preservative-containing topical medications.